Scientific significance of clinically insignificant FcγRIIIa-V158F polymorphism

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 787-789

  Cartron, Guillaume ^a   Houot, Roch ^b,c   Kohrt, Holbrook E ^d  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD20 ANTIGEN; CETUXIMAB; CHLORAMBUCIL; FC RECEPTOR IIA; FC RECEPTOR IIIA; IMMUNOGLOBULIN G1; OBINUTUZUMAB; PHENYLALANINE; RITUXIMAB; TRASTUZUMAB; UBLITUXIMAB; UNCLASSIFIED DRUG; VALINE; FC RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; HUMAN; IN VIVO STUDY; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; GENETICS; LYMPHOMA, FOLLICULAR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; LYMPHOMA, FOLLICULAR; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RITUXIMAB;

EID: 84964222484     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2777     Document Type: Article

References (13)

1. Kenkre VP, Hong F, Cerhan JR, Lewis M, Sullivan L, Williams ME, et al. Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma. Clin Cancer Res 2016;22:821-6.
2. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, De Haas M: Fc gRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gRIIIa, independently of the Fc gRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
3. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100: 1059-70.
4. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99: 754-8.
5. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
6. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
7. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
8. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-10.
9. Sehn LH, Goy A,Offner FC,Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study. J Clin Oncol 2015;33: 3467-74.
10. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphism may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
11. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4464-9.
12. Dayd-e D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: Pharmacokinetic-pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009;113:3765-72.
13. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between FcgRIIIa-V158F and FcgRIIa-H131R polymorphism in white patients and restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008;26:5489-90.